ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1243

Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis

Seiji Nakamura1, Hiroshi Iijima1, Yuko Hata2, Yohei Ishizawa2, Chun Ren Lim2, Ryo Matoba2, Katsuya Suzuki3, Koichi Amano4 and Tsutomu Takeuchi3, 1Kanagawa, DNA Chip Research Inc., Yokohama, Japan, 2DNA Chip Research Inc., Yokohama, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 4Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic agents, Biomarkers, Gene Expression, leukocytes and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:
Employing
genome-wide gene transcription on a unified platform, to identify molecular signatures
for predicting therapeutic effects for rheumatoid arthritis (RA) with three
biologics, infliximab (IFX), tocilizumab (TCZ), and abatacept (ABT).

Methods: Two hundred and
three RA patients who were methotrexate-inadequate response and the first
biologic administered were enrolled (IFX: 139, TCZ: 34, ABT: 30). Whole blood
gene transcription data of each patient were obtained using a unified platform,
Agilent Whole Genome Microarray 44K prior to administration of drugs. Using
gene set enrichment analysis (GSEA), a priori defined functional set of genes,
such as Reactome pathways and blood cell subtype-specific transcripts, were
analyzed to find the difference of biological characteristics between remittors
and non-remittors based on CDAI at 6th month of treatment. “Signature scores”
of the gene sets derived from the GSEA results was calculated for each patient
and then was reviewed using logistic regression and ROC analysis.

 

Results: Based on GSEA,
innate immunity pathways (inflammasomes and negative regulators of RIG-I/MDA5
signaling) were significantly upregulated in baseline peripheral blood of
non-remitters in IFX (table 1). In TCZ, genes specifically expressed in B or T
cells were significantly upregulated in remitters. Apoptosis related or NK
cells-specific genes were related with ABT treatment outcome. Univariate
logistic regression of signature scores supported the GSEA results.
Multivariate logistic regression adjusting to clinical background showed
inflammasomes genes for IFX, CD19 cells-specific genes for TCZ, CD56
cells-specific genes for ABT as significant independent predictive factors. The
AUCs of ROC curve of each signature score were 0.638 (95% CI: 0.538-0.739), 0.769
(95% CI: 0.596-0.943), and 0.764 (95% CI: 0.575-0.953) for IFX, TCZ, and ABT,
respectively.

Conclusion:
We
have shown a long sought objective means to predict the therapeutic effects of
biologics using multiple expression markers expressed in peripheral blood. Each
signature is shown to be associated with biological function underlying the
therapeutic mechanism.


Disclosure: S. Nakamura, DNA Chip Research Inc., 3; H. Iijima, DNA Chip Research Inc., 3; Y. Hata, DNA Chip Research Inc., 3; Y. Ishizawa, DNA Chip Research Inc., 3; C. R. Lim, DNA Chip Research Inc., 3; R. Matoba, DNA Chip Research Inc., 3,DNA Chip Research Inc., 1; K. Suzuki, None; K. Amano, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Nakamura S, Iijima H, Hata Y, Ishizawa Y, Lim CR, Matoba R, Suzuki K, Amano K, Takeuchi T. Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-of-the-gene-expression-signatures-predicting-the-responses-to-three-biologics-infliximab-tocilizumab-and-abatacept-in-rheumatoid-arthritis/. Accessed February 23, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-the-gene-expression-signatures-predicting-the-responses-to-three-biologics-infliximab-tocilizumab-and-abatacept-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Chicago, IL

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.